Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 16Male Urogenital Diseases 3Prostatic Intraepithelial Neoplasia 2Uremia 1Prostatic Hyperplasia 1Neoplasms 1Neoplasm Metastasis 1Disease Progression 1Colorectal Cancer Metastatic 1Carcinoma, Transitional Cell 1

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Paclitaxel 2Doxorubicin 2Bevacizumab 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1nilotinib 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Disease Progression × Lycopene × Clear all
NCT00172367 2008-09-26

Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma

National Taiwan University Hospital

Phase 2 Withdrawn
80 enrolled
Genitourinary

Carcinoma, Transitional Cell, Uremia, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡